Evidence map›Paper›PMID 35028815›Full record

ReviewCurrent cardiology reports2022

Role of Monotherapy with a P2Y12 Inhibitor for Secondary Prevention in Patients with Established Atherosclerosis.

Juan J Rodriguez, Luis E Baron, Oscar C Munoz, Jonathan J Diaz

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current cardiology reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 100% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 2 countries.

Juan J RodriguezTexas Tech University Health Sciences Center, El paso, TX, USA.
Luis E BaronTexas Tech University Health Sciences Center, El paso, TX, USA.
Oscar C MunozTexas Tech University Health Sciences Center, El paso, TX, USA. omunoz1968@hotmail.com.ORCID http://orcid.org/0000-0002-6384-8768
Jonathan J DiazFacultad de Medicina, Universidad Autonoma de Bucaramanga, Bucaramanga, Colombia.
Texas Tech University · USUniversidad Autónoma de Bucaramanga · CO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purpose of reviewThe role of monotherapy with a P2Y12 inhibitor for secondary prevention of cardiovascular diseases has been assessed in several randomized trials. In this article, we summarize the evidence regarding P2Y12 monotherapy for secondary prevention in each one of the major vascular territories. RECENT

findingsAvailable data including a large recent meta-analysis show no differences in terms of all-cause death, vascular death, stroke, and a minor difference of the risk of myocardial infarction with P2Y12 monotherapy as compared to dual antiplatelet therapy. Overall, mono antiplatelet therapy with aspirin and the P2Y12 inhibitors appear similar in efficacy. However, there are clinical conditions that may suggest one drug regimen over another in secondary prevention. The risk of bleeding must always be weighed in each patient individually for the optimal choice of the antiplatelet regimen.

Indexed as

AtherosclerosisMyocardial InfarctionPercutaneous Coronary InterventionHumansPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsSecondary PreventionPlatelet Aggregation InhibitorsPurinergic P2Y Receptor AntagonistsAntiplatelet therapyAtherosclerosic diseaseMonotherapyMyocardial infarctionPeripheral arterial diseaseSecondary preventionStroke

Identifiers

PMID35028815
OpenAlexW4205845043

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.